Organization
Qilu Hospital of Shandong University, Department of Rheumatology, Jinan, China
2 abstracts
Abstract
A PHASE III, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED CLINICAL TRIAL TO COMPARE BAT1806/BIIB800, A PROPOSED TOCILIZUMAB BIOSIMILAR, WITH TOCILIZUMAB REFERENCE PRODUCT IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE THERAPYOrg: Peking Union Medical College Hospital, Department of Rheumatology and Clinical Immunology, Beijing, China, Poznan University of Medical Sciences, Department of Rheumatology, Poznan, Poland, Clinic and Department of Rheumatology and Connective Tissue Diseases University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Toruń, Department of Rheumatology and Connective Tissue Diseases, Toruń, Poland, First Affiliated Hospital of Zhengzhou University, Department of Rheumatology and Immunology, Zhengzhou, China, Qilu Hospital of Shandong University, Department of Rheumatology, Jinan, China,
Abstract
A MULTICENTER RANDOMIZED STUDY IN RHEUMATOID ARTHRITIS TO COMPARE IGURATIMOD, METHOTREXATE, OR COMBINATION: 52 WEEK EFFICACY AND SAFETY RESULTS OF THE SMILE TRIALOrg: Renji Hospital of Shanghai Jiao Tong University School of Medicine, Department of Rheumatology, Shanghai, China, The First Affiliated Hospital of Anhui Medical University, Department of Rheumatology and Immunology, Hefei, China, The First Affiliated Hospital of USTC, Department of Rheumatology and Immunology, Hefei, China, Peking University People’s Hospital, Department of Rheumatology and Immunology, Beijing, China, Qilu Hospital of Shandong University, Department of Rheumatology, Jinan, China,